Gene Ontology annotation through association of InterPro records with GO terms

Annotation inferences using phylogenetic trees

Automatic transfer of experimentally verified manual GO annotation data to orthologs using Ensembl Compara

Electronic Gene Ontology annotations created by ARBA machine learning models

Combined Automated Annotation using Multiple IEA Methods

Physiological fIXa activation involves a cooperative conformational rearrangement of the 99-loop.

The human plasma proteome: a nonredundant list developed by combination of four separate sources.

Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody.

X-linked thrombophilia with a mutant factor IX (factor IX Padua).

Structure based drug design: development of potent and selective factor IXa (FIXa) inhibitors.

Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis.

In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.

Three point mutations in the factor IX genes of five hemophilia B patients. Identification strategy using localization by altered epitopes in their hemophilic proteins.

Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver.

Blood clotting factor IX BM Nagoya. Substitution of arginine 180 by tryptophan and its activation by alpha-chymotrypsin and rat mast cell chymase.

Human coagulation factor VIII domain-specific recombinant polypeptide expression.

Notch-modifying xylosyltransferase structures support an SNi-like retaining mechanism.

Evidence for a prevalent dimorphism in the activation peptide of human coagulation factor IX.

The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation by factor XIa.

Structural integrity of the gamma-carboxyglutamic acid domain of human blood coagulation factor IXa Is required for its binding to cofactor VIIIa.

Modification of the N-terminus of human factor IX by defective propeptide cleavage or acetylation results in a destabilized calcium-induced conformation: effects on phospholipid binding and activation by factor XIa.

factor X -> factor Xa + factor X activation peptide (VIIIa:IXa catalyst)

factor VIIIa + factor IXa -> factor VIIIa:factor IXa

factor IX -> factor IXa + factor IX activation peptide (factor XIa catalyst)

Furin cleaves pro-factor IX to factor IX

GGCX gamma-carboxylates 3D-F9(29-461) (pro-factor IX)

Gamma-carboxy pro-factor IX transport from the endoplasmic reticulum to the Golgi apparatus

factor IXa associates with cell membrane

Hyperactivation of factor X by FVIIIa:FIXa R384L

FVIIIa variant:FIXa does not convert FX to the active FXa

Factor IXa binds protein S

FIX is secreted

FIXa variant:FVIIIa does not convert FX to the active FXa

F9 variant is not secreted

FIX(29-461) variant is not activated (factor XIa catalyst)

GGCX does not gamma-carboxylate 3D-F9(29-461) (pro-factor IX)

Factor IXa binds emicizumab

factor X -> factor Xa + factor X activation peptide (emicizumab:FIXa catalyst)

TF:FVIIa+FIX -> TF:FVIIa:FIXa + FIX activation peptide (TF:F7a catalyst)

TF:FVIIa:FIXa ->TF:FVIIa + FIXa

factor IX -> factor IXa + factor IX activation peptide (kallikrein catalyst)

Creation of a mouse expressing defective human factor IX.

Ixodes ricinus Salivary Serpin Iripin-8 Inhibits the Intrinsic Pathway of Coagulation and Complement.

A sequential mechanism for exosite-mediated factor IX activation by factor XIa.

Molecular basis of vitamin-K-driven γ-carboxylation at the membrane interface.

UniProtKB entry P00740 (FA9_HUMAN)